Skip to main content
NVDA+0.14%AAPL+0.02%GOOGL-0.63%MSFT-0.03%AMZN+0.24%TSM-3.01%SPCX-4.19%META-0.23%AVGO-4.35%TSLA-0.03%SKHY-4.35%MU+0.17%BRK-B+0.95%LLY-1.61%AMD-3.90%JPM+0.56%WMT+2.22%ASMLa+1.27%V+0.81%XOM+2.75%JNJ-0.76%INTC-5.34%MA+0.82%0700.HK+1.89%ABBV+0.39%CSCO-2.13%1398.HK-0.69%CVX+3.12%COST+0.60%AP2d-0.09%AMAT-2.13%LRCX-2.71%ORCL-5.48%DELL-0.76%BAC+0.17%KO+2.27%CAT-2.17%PG+1.87%1816.HK-26.47%UNH-1.34%3988.HK+1.12%0005.HK+1.80%GE+0.66%HSBA.L-1.95%PM+4.05%0857.HK+0.20%0939.HK+0.96%NFLX+2.68%MS-1.20%HD+3.39%AUDCHF+0.61%AUDJPY+0.54%EURAUD-0.54%EURCAD-0.48%CADCHF+0.47%USDTRY+0.44%CADJPY+0.43%GBPTRY+0.41%USDZAR-0.40%GBPAUD-0.34%AUDUSD+0.33%GBPHKD+0.32%NZDCHF+0.31%GBPZAR-0.31%EURNZD-0.31%NOKJPY+0.29%GBPMXN-0.28%PLNJPY+0.28%NZDJPY+0.27%USDCAD-0.26%EURZAR-0.25%GBPCAD-0.25%EURGBP-0.23%SGDJPY+0.23%AUDNZD+0.22%GBPCHF+0.22%EURUSD-0.22%USDCHF+0.21%NZDSGD+0.20%AUDSGD+0.18%USDJPY+0.17%GBPJPY+0.17%USDSEK-0.16%USDILS+0.16%NZDCAD-0.16%NZDMXN+0.16%USDNOK-0.16%USDDKK-0.15%EURHKD+0.14%USDPLN-0.13%USDMXN-0.12%AUDNOK+0.11%AUDDKK+0.11%NZDUSD+0.10%USDCNH-0.10%GBPNZD-0.08%USDSGD-0.08%EURJPY-0.07%EURSGD+0.07%CHFSGD+0.06%EURCNH+0.06%AUDCAD+0.05%CHFJPY-0.04%USDCOP-0.04%USDTHB-0.04%CHFSEK-0.03%EURSEK-0.02%EURCZK+0.02%EURCHF-0.02%GBPSGD+0.02%GBPUSD+0.01%CHFNOK-0.01%EURPLN+0.01%EURNOK-0.01%EURDKK-0.01%USDHKD0.00%XPTUSD+2.02%XAGUSD+1.81%GAGUSD+1.81%HG1+1.38%GAUUSD+1.18%XAUUSD+1.18%UKOIL-1.16%USOIL-1.03%S1+0.76%COTTON+0.69%C1+0.45%W1+0.42%BTCUSD-1.28%ETHUSD+11.79%USDTUSD-0.04%XRPUSD+5.55%SOLUSD+1.82%TRXUSDT-1.00%ZECUSDT-8.17%DOGEUSD+5.25%XMRUSDT-3.09%LINKUSD+7.35%XLMUSD-2.98%BCHUSDT-6.89%LTCUSD+1.20%UNIUSD-7.33%SUIUSD-6.75%HBARUSDT-1.48%TONUSD+18.86%TAOUSDT-6.29%AAVEUSD-5.18%DOTUSDT+3.81%ICPUSDT-6.76%ONDOUSDT+1.15%WLDUSDT-6.00%JUPUSDT-2.00%ARBUSDT-4.87%ATOMUSDT+7.80%STXUSDT+5.88%INJUSDT-6.94%FETUSDT-4.14%PYTHUSDT+11.81%TIAUSDT+11.01%SEIUSDT-3.41%IMXUSDT+5.69%GRTUSDT-3.79%OPUSDT-0.41%IOTAUSDT-5.67%WIFUSDT-8.29%AXSUSDT-5.39%POLUSDT-2.63%FARTCOINUSDT+1.02%EOSUSDT+0.64%DYDXUSDT+0.40%GALAUSDT-4.26%ORDIUSDT-6.27%RONINUSDT-2.67%NOTUSDT-5.84%NVDA+0.14%AAPL+0.02%GOOGL-0.63%MSFT-0.03%AMZN+0.24%TSM-3.01%SPCX-4.19%META-0.23%AVGO-4.35%TSLA-0.03%SKHY-4.35%MU+0.17%BRK-B+0.95%LLY-1.61%AMD-3.90%JPM+0.56%WMT+2.22%ASMLa+1.27%V+0.81%XOM+2.75%JNJ-0.76%INTC-5.34%MA+0.82%0700.HK+1.89%ABBV+0.39%CSCO-2.13%1398.HK-0.69%CVX+3.12%COST+0.60%AP2d-0.09%AMAT-2.13%LRCX-2.71%ORCL-5.48%DELL-0.76%BAC+0.17%KO+2.27%CAT-2.17%PG+1.87%1816.HK-26.47%UNH-1.34%3988.HK+1.12%0005.HK+1.80%GE+0.66%HSBA.L-1.95%PM+4.05%0857.HK+0.20%0939.HK+0.96%NFLX+2.68%MS-1.20%HD+3.39%AUDCHF+0.61%AUDJPY+0.54%EURAUD-0.54%EURCAD-0.48%CADCHF+0.47%USDTRY+0.44%CADJPY+0.43%GBPTRY+0.41%USDZAR-0.40%GBPAUD-0.34%AUDUSD+0.33%GBPHKD+0.32%NZDCHF+0.31%GBPZAR-0.31%EURNZD-0.31%NOKJPY+0.29%GBPMXN-0.28%PLNJPY+0.28%NZDJPY+0.27%USDCAD-0.26%EURZAR-0.25%GBPCAD-0.25%EURGBP-0.23%SGDJPY+0.23%AUDNZD+0.22%GBPCHF+0.22%EURUSD-0.22%USDCHF+0.21%NZDSGD+0.20%AUDSGD+0.18%USDJPY+0.17%GBPJPY+0.17%USDSEK-0.16%USDILS+0.16%NZDCAD-0.16%NZDMXN+0.16%USDNOK-0.16%USDDKK-0.15%EURHKD+0.14%USDPLN-0.13%USDMXN-0.12%AUDNOK+0.11%AUDDKK+0.11%NZDUSD+0.10%USDCNH-0.10%GBPNZD-0.08%USDSGD-0.08%EURJPY-0.07%EURSGD+0.07%CHFSGD+0.06%EURCNH+0.06%AUDCAD+0.05%CHFJPY-0.04%USDCOP-0.04%USDTHB-0.04%CHFSEK-0.03%EURSEK-0.02%EURCZK+0.02%EURCHF-0.02%GBPSGD+0.02%GBPUSD+0.01%CHFNOK-0.01%EURPLN+0.01%EURNOK-0.01%EURDKK-0.01%USDHKD0.00%XPTUSD+2.02%XAGUSD+1.81%GAGUSD+1.81%HG1+1.38%GAUUSD+1.18%XAUUSD+1.18%UKOIL-1.16%USOIL-1.03%S1+0.76%COTTON+0.69%C1+0.45%W1+0.42%BTCUSD-1.28%ETHUSD+11.79%USDTUSD-0.04%XRPUSD+5.55%SOLUSD+1.82%TRXUSDT-1.00%ZECUSDT-8.17%DOGEUSD+5.25%XMRUSDT-3.09%LINKUSD+7.35%XLMUSD-2.98%BCHUSDT-6.89%LTCUSD+1.20%UNIUSD-7.33%SUIUSD-6.75%HBARUSDT-1.48%TONUSD+18.86%TAOUSDT-6.29%AAVEUSD-5.18%DOTUSDT+3.81%ICPUSDT-6.76%ONDOUSDT+1.15%WLDUSDT-6.00%JUPUSDT-2.00%ARBUSDT-4.87%ATOMUSDT+7.80%STXUSDT+5.88%INJUSDT-6.94%FETUSDT-4.14%PYTHUSDT+11.81%TIAUSDT+11.01%SEIUSDT-3.41%IMXUSDT+5.69%GRTUSDT-3.79%OPUSDT-0.41%IOTAUSDT-5.67%WIFUSDT-8.29%AXSUSDT-5.39%POLUSDT-2.63%FARTCOINUSDT+1.02%EOSUSDT+0.64%DYDXUSDT+0.40%GALAUSDT-4.26%ORDIUSDT-6.27%RONINUSDT-2.67%NOTUSDT-5.84%
RE

Repligen Corporation (RGEN)

NASDAQ • Healthcare

$163.84
-$3.37 (-2.0%)
Market closed

Last close at October 8, 2026 at 20:00 UTC

Open$163.83
Day Range$157.49 - $166.37
Avg. Volume (3M)1.2M
Market Cap$9.2B
P/E Ratio221.4
52 Week Range
$100.99$198.87
Next EarningsIn 25 daysNov 3, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$204.1M100%
Gross Profitminus cost of goods$108.3M53%
Operating Incomeminus R&D and overhead$11.9M6%
Net Incomeminus taxes and the rest$5M2%

In plain terms: out of every $100 in revenue, Repligen Corporation keeps $2 as net profit.

Fundamentals & Financials

Revenue (TTM)
$785.1M
Net Income (TTM)
$41.5M
EPS (TTM)
$0.74
ROA (TTM)
1.41%
Current Ratio
9.05

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+11.4%Q1 2026$0.49
+26.3%Q2 2026$0.48
+20.8%Q3 2026$0.54
Next

Nov 3

in 25 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +20.8%

Repligen beat expectations on both the top and bottom line in the second fiscal quarter of 2026, reported July 28, with adjusted EPS of $0.54 topping the $0.45 estimate (+21%) and revenue of $204.1 million topping the $201.6 million estimate (+1.3%). Revenue rose ~12% to about $204.1 million from roughly $182.4 million a year ago, while net income fell ~66% to around $5.0 million versus about $14.9 million in the prior-year quarter. Profitability included gross profit of roughly $108.4 million and a gross margin near 53%, alongside operating income of about $11.9 million for an operating margin around 6%. The company generated operating cash flow of approximately $32.8 million and repurchased about $1.1 million of stock. Next-period consensus calls for EPS of $0.46 on revenue of $206.8 million.

Next report — what to expect

Repligen Corporation (RGEN) is set to report earnings on November 3, 2026. Wall Street’s consensus calls for EPS of $0.46 on revenue of $206.7 million. For trailing context, revenue grew +11.9% year over year last quarter. Repligen has beaten EPS in 7 of 8 most recent quarters, making margins and demand trends key items to watch.

View full earnings history

About Repligen Corporation

Repligen Corporation develops and sells bioprocessing equipment, materials, and integrated systems for biologic drug manufacturing and related laboratory work. Listed on the NASDAQ as RGEN, the healthcare company operates in the medical instruments and supplies business and generated $738.3 million of revenue in FY2025.

Name
Repligen Corporation
CEO
Olivier Loeillot
Website
www.repligen.com
Industry
Healthcare
Year Founded
1981
Employees
2,000

Today's Snapshot

AI-generated

RGEN closed 2% below yesterday's close, while its sector was flat. Repligen's deal with BioLife Solutions, a lab supplier, unsettled investors.

Trading Volume

Below 10d avg (1.5M)

1.2M

vs S&P 500 Today

Underperforming Market

-1.48%

Updated: October 8, 2026 at 20:19 UTC

RGEN Headlines

Healthcare stocks fall after weak US jobs data

March 6, 2026

3 min read
View All News

Technical Indicators

3 Buy2 Neutral3 Sell
RGEN reflects a balance of conflicting signals that produce a neutral posture: the price sits below short and medium moving averages but above the 100- and 200-day averages, and momentum is mixed with a lowish RSI, a positive but mild MACD and a deeply negative CCI. ADX registers in the low 30s, indicating a meaningful trend that currently aligns with downside pressure, while ATR is elevated and on-balance volume is negative. The pivot is nearby and noncommittal. Technical takeaway: Neutral — short-term weakness contrasts with longer-term moving-average support, producing an ambiguous technical picture.
All signals
  • EMA (5 indicators)$153.22 - $178.41
    Sell
  • RSI (14)39.87
    Neutral
  • Stochastic %K (14, 3, 3)8.50
    Buy
  • MACD Level (12, 26)0.86
    Neutral

Peers & Related Assets

TMOThermo Fisher Scientific Inc.
$651.98-1.5%
AAgilent Technologies, Inc.
$168.17-0.5%
TECHBio-Techne Corporation
$72.45-0.1%
AVTRAvantor, Inc.
$15.39+0.3%
BIOBio-Rad Laboratories, Inc.
$360.4-2.0%
QGENQiagen N.V.
$44.53-0.6%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.